In a pi­o­neer­ing first, As­traZeneca scores FDA OK to use its PARP against breast can­cer

As­traZeneca $AZN has picked up an­oth­er key win for its can­cer drug fran­chise.

The FDA ap­proved its PARP in­hibitor Lyn­parza for BR­CA-mu­tat­ed metasta­t­ic breast can­cer, of­fer­ing the phar­ma gi­ant a path for­ward to ex­pand its use be­yond ovar­i­an can­cer. And this is a first in the field.

Their Phase III da­ta made the show­case round at AS­CO last sum­mer and is fur­ther en­hanc­ing the FDA’s fo­cus on drugs that can tar­get can­cers trig­gered by the same ge­net­ic caus­es. The drug was linked with tu­mor shrink­age in 60% of the pa­tients with germline BR­CA1 or BR­CA2 mu­ta­tions tak­ing the drug, com­pared to 29% in the chemo group. And the OK gives them an edge over their ri­vals: Clo­vis’ Rubra­ca and Tesaro’s Ze­ju­la.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA